Fifty-two patients with Fredrickson Type IIb or Type IV hyperlipidaemia, in whom diet had not achieved satisfactory lipid levels, completed a double blind randomised study of acipimox versus placebo. The patients were given acipimox, 250 mg three times daily or placebo for a three month period, and plasma lipids and glucose were monitored. The patients receiving acipimox showed a fall in the mean concentration of plasma triglyceride compared to placebo (0.74 mmol/l) and this was most marked in patients whose initial plasma triglyceride levels were greater than 3 mmol/l (1.0 mmol/l, confidence limits 0.18, 1.82). Acipimox was well tolerated, and could be a useful addition to the drugs available for the treatment of patients with hypertriglyceridaemia. © 1986 Springer-Verlag.
CITATION STYLE
Ball, M. J., Vella, M., Rechlass, J. P. D., Jones, D. B., Stirling, C., Mann, J. I., & Galton, D. (1986). Acipimox in the treatment of patients with hyperlipidaemia: A double blind trial. European Journal of Clinical Pharmacology, 31(2), 201–204. https://doi.org/10.1007/BF00606659
Mendeley helps you to discover research relevant for your work.